Chemomab Therapeutics (CMMB) Cash from Operations (2017 - 2023)
Chemomab Therapeutics' (CMMB) quarterly Cash from Operations came in at 3717000.0 in Q4 2023, up 34.82% YoY from 2756932.11 in Q4 2022, and up 28.82% on a QoQ basis from 5222000.0 in Q3 2023.
Chemomab Therapeutics (CMMB) Cash from Operations (2017 - 2023) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Cash from Operations data on file, last reported at 3717000.0 in Q4 2023.
- Quarterly Cash from Operations rose 34.82% year-over-year to 3717000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 23611000.0 (down 15.91% YoY) and the FY2025 annual result came in at 11130000.0, up 27.66% from the prior year.
- Cash from Operations rose to 3717000.0 in Q4 2023, from 5222000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 873000.0 in Q2 2020 to a low of 7486000.0 in Q2 2023.
- A 5-year average of 3902750.0 and a median of 3714000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2020 — Cash from Operations jumped 77.7% — and 2021, when it tumbled 542.27%.
- Tracing CMMB's Cash from Operations over 5 years: stood at 5914000.0 in 2019, then surged by 73.71% to 1555000.0 in 2020, then slumped by 86.11% to 2894000.0 in 2021, then sank by 97.06% to 5703000.0 in 2022, then surged by 34.82% to 3717000.0 in 2023.
- The last three Cash from Operations figures came in at 3717000.0 (Q4 2023), 5222000.0 (Q3 2023), and 7486000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -3.72 Mn |
| Dec 31, 2023 | -3.72 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Jun 30, 2023 | -7.49 Mn |
| Jun 30, 2023 | -7.49 Mn |
| Mar 31, 2023 | -7.19 Mn |
| Mar 31, 2023 | -7.19 Mn |
| Dec 31, 2022 | -5.70 Mn |
| Dec 31, 2022 | -5.70 Mn |
| Sep 30, 2022 | -5.26 Mn |
| Sep 30, 2022 | -5.26 Mn |
| Jun 30, 2022 | -5.70 Mn |
| Jun 30, 2022 | -5.70 Mn |
| Mar 31, 2022 | -3.71 Mn |
| Mar 31, 2022 | -3.71 Mn |
| Dec 31, 2021 | -2.89 Mn |
| Dec 31, 2021 | -2.89 Mn |
| Sep 30, 2021 | -2.58 Mn |
| Sep 30, 2021 | -2.58 Mn |